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illustrated by the novel observation that the proportion of GalCer with hydroxylated fatty acids increased 
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Synopsis 
Current lipidomic profiling methods rely mainly on mass spectrometry to identify unknown lipids 
within a complex sample. We describe a new approach, involving LC×MS/MS analysis of 
sphingolipids based on both mass and hydrophobicity, and use this method to characterize the 
sphingomyelin (SM), ceramide, and galactosylceramide (GalCer) content of hippocampus from 
Alzheimer’s Disease (AD) and control subjects. Using a mathematical relationship we exclude the 
influence of sphingolipid mass on retention time, and generate two-dimensional plots that facilitate 
accurate visualization and characterization of the different ceramide moieties within a given 
sphingolipid class, because related molecules align horizontally or vertically on the plots. Major brain 
GalCer species that differ in mass by only 0.04 Da were easily differentiated on the basis of their 
hydrophobicity. The importance of our method’s capacity to define all of the major GalCer species in 
the brain samples is illustrated with the novel observation that the proportion of GalCer with 
hydroxylated fatty acids increased approximately two-fold in the hippocampus of AD patients, 
compared to age- and gender-matched controls. This suggests activation of fatty acid hydroxylase in 
AD. Our method greatly improves the clarity of data obtained in a lipid profiling experiment and can 








AD, Alzheimer’s Disease; GluCer, glucosylceramide; GalCer, galactosylceramide; HFA, 
hydroxylated fatty acid; LC, liquid chromatography; MRM, multiple reaction monitoring; MS, mass 





The sphingolipids are a diverse family of structural and signaling lipids that have a broad range of 
functions in normal physiology and pathology [1, 2]. Altered sphingolipid metabolism has been 
implicated in the pathology of cancer [2], cardiovascular diseases [3], type II diabetes [4], and 
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neurodegenerative diseases such as Parkinson’s disease [5] and AD [6]. The common constituent of 
all sphingolipids is the sphingoid base, which in mammals is most commonly 18-carbon sphingosine 
or dihydrosphingosine. A family of six ceramide synthases catalyze the transfer of fatty acids to the 
amine group of sphingosine or dihydrosphingosine, forming the central sphingolipid metabolite 
ceramide (Figure 1a). The fatty acids vary in length from 14 to 26 carbons, may contain one or more 
double bonds, and may be hydroxylated. These variations create significant structural and biophysical 
heterogeneity within ceramides. Addition of different headgroups to the primary hydroxyl of 
ceramides gives rise to the different classes of sphingolipids, which are all built on a ceramide lipid 
“backbone”.  
 
Ceramide is itself a signaling molecule that is frequently associated with execution of apoptosis [2], 
but also plays a role in establishing epithelial cell polarity [7] and the formation of cell-cell junctions 
[8]. The abundant plasma membrane lipid SM is formed by the transfer of a phosphatidylcholine 
headgroup onto ceramide (Figure 1a). The interaction of SM with cholesterol gives rise to lipid rafts, 
specialized regions of the plasma membrane where cell signaling platforms are formed. Alternatively, 
glucose, galactose, or phosphate headgroups may be transferred onto ceramide, giving rise to lipid 
mediators with distinct functions. GalCer may be sulfated (forming sulfatide), and both of these lipids 
are major constituents of myelin. Accordingly, GalCer synthesis is critical for normal brain function 
[9, 10].  
 
The aim of this research project was to develop a two-dimensional (2D) sphingolipid profiling 
approach, in which the lipids are separated and identified on the basis of both mass and 
hydrophobicity. Sphingolipids in biological samples are usually quantified using Liquid 
Chromatography-tandem Mass Spectrometry (LC-MS/MS). In general, a defined number of lipid 
metabolites are quantified by running the mass spectrometer in Multiple Reaction Monitoring (MRM) 
mode, in which a specific precursor and product ion mass are used to identify each metabolite of 
interest, which is quantified relative to external standards [11, 12]. However, MRM assumes prior 
knowledge about which lipids are present in a given extract. A more objective profiling approach can 
be achieved by scanning for precursor ions within a defined mass range, whilst monitoring for product 
ions that are characteristic of a particular lipid backbone, e.g. sphingosine (m/z 264) or 
dihydrosphingosine (m/z 266) [12]. Lipids identified using this approach may then be quantified more 
accurately in a follow-up MRM experiment. However, assigning a molecular structure to a given lipid 
based only on its precursor and product masses is not always feasible, because a given mass can often 
be assigned to two or more biologically relevant structures.  
 
Incorporating an LC step prior to MS/MS improves sensitivity by removing interfering ions, 
separating out different lipid components in the cell or tissue extract, and concentrating each lipid 
species into a narrow elution time window. In theory, the incorporation of an LC column prior to MS 
can also provide biochemical information that helps to definitively assign a structure to a given 
precursor and product mass. However, LC is not used in mass scanning/profiling experiments, firstly 
because column Retention Time (RT) is not informative unless referenced to structurally defined 
standards; and secondly because in reverse phase chromatography of lipids with the same headgroup, 
differences in mass conferred by different acyl chain lengths have a large impact on RT. To 
effectively use RT in the characterization of unknown lipids from a lipid profiling experiment, we 
first needed to develop a method in which RT is made independent of N-acyl chain length, and 
therefore mass. To do this we adapted and modified a method that was used for separation of 
hydrocarbons [13, 14] and fatty acid methyl esters [15, 16].  
 
We describe here an LC×MS/MS approach (as distinct from an LC-MS/MS approach) for 
characterization of sphingolipids in complex biological extracts that we refer to as Mass and Relative 
Elution Time (MRET) profiling. After excluding the influence of mass on RT for any given class of 
sphingolipid, the resulting 2D plots can be used to predict the number and position of double bonds 
within the lipid tails, and the presence of functional groups such as hydroxyls, without any need for 
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chemical derivatization of the lipids or the use of high resolution mass analyzers. We describe how 
this approach can be used to collate the MS output of brain tissue extracts from twelve different 
human subjects, forming 2D plots of the SM, ceramide, and GalCer content that also incorporate a 
semi-quantitative measure of relative abundance for each distinct metabolite. These plots are an 
informative and versatile way to visualize complex lipidomic data sets. Importantly, we show how 
this approach allows us to distinguish between GalCer species that are structurally and biochemically 




Liquid Chromatography and Mass Spectrometry  
LC-MS/MS was performed on a Thermo TSQ triple quadrupole mass spectrometer, operating in 
positive ion mode, coupled to a 3 x 150 mm Agilent XDB-C8 column (5 micron pore size) on an 
Accela UPLC system (Thermo). In both methods, lipids were separated using a binary gradient 
program, at a flow rate of 0.5 mL/min: mobile phase A was 0.2% formic acid/2 mM ammonium 
formate in water; mobile phase B was 0.2% formic acid/1 mM ammonium formate in methanol. The 
HPLC gradient for separation of ceramide and GalCer was as follows: 0 min, 20:80 A/B; 2 min, 15:85 
A/B; 3min, 10:90 A/B; 4 min, 1:99 A/B; 5 min 0:100 A/B; 18 min 0:100 A/B; 20 min 20:80 A/B. C18 
chromatography was performed on a 2 x 150 mm Phenomenex C18 column (3 micron pore size). The 
gradient employed was: 0 min, 10:90 A/B; 2 min, 0/100 A/B; 43 min, 0/100 A/B; 45 min, 10/90 A/B. 
The HPLC gradient for separation of SM (on the C8 column) was: 0 min, 20:80 A/B; 2 min, 10:90 
A/B; 3 min, 1:99 A/B; 19 min, 1/99 A/B; 20 min, 20:80 A/B; 22 min, 20:80 A/B.  
 
Ceramide and GalCer were analyzed simultaneously by precursor ion scanning over the mass range 
450 to 1050 Da, monitoring for m/z 262.0, 264.1, and 266.1 product ions at collision energy 30 eV. 
For clarity this paper describes results derived primarily from the m/z 264 product ion scan. Scan time 
was one second for each event (i.e. each scan was run every three seconds). SM species were detected 
separately, monitoring for an m/z 184 product ion at collision energy 35 eV. For ceramide standards 
run over a broad concentration range, from 8 nM to 8 µM (total 6 concentrations), in precursor 
scanning mode, Coefficient of Variation (CV) in m/z of LC peaks ranged from 0.005 to 0.06, whilst 
CV in RT ranged from 0.018 to 0.407. Variation in retention time between the start and the end of a 
sequence of 18 samples (i.e. 6 hours apart) was less than 1% for three different GalCer standards: 
d18:1/12:0, RT = 6.88 and 6.88 min; d18:1/18:0, RT = 8.42 and 8.36 min; d18:1/24:1, RT = 10.39 
and 10.33 min. For lipid detection in MRM mode, the TSQ was set to monitor a list of events as 
shown in Table 1, each with a scan time of 0.06 seconds. Note that mass accuracy for the Quantum 
TSQ is ± 0.5 Da. 
 
High mass accuracy analysis of GalCer species was performed using an LTQXL Orbitrap Mass 
Spectrometer operating in positive [electrospray] mode, connected to an Accela liquid 
chromatography system (Thermo Scientific). The gradient program, at flow rate 0.4 mL/min, was as 
follows: 0 min, 20:80 A/B; 2.5 min, 15:85 A/B; 3.8min, 10:90 A/B; 5 min, 1:99 A/B; 6.5 min 0:100 
A/B; 30 min 0:100 A/B; 32 min 20:80 A/B. Mass spectra were recorded in Fourier Transform full 
scan mode, mass range 80 - 1100 Da, mass resolution 60000 (m/∆m, FWHM at 400 Da).  
 
Lipid Extraction from Human Brain Tissue 
Human brain tissues were obtained from the Sydney Brain Bank and the New South Wales Tissue 
Resource Centre. Ethics approval for the current study was from the University of Wollongong 
Human Research Ethics Committee (HE10/327). Tissue samples were obtained from brains of six AD 
patients, clinically and pathologically defined using NIA-Reagan criteria, and six age- and gender-
matched controls [17]. These 12 samples have been used in another, unrelated study [18]. Clinical 
information for each case including gender, age at death, post-mortem interval (PMI), and clinical 
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cause of death is provided in Table 2. Frozen brain tissue from the hippocampus and cerebellum was 
pulverized over dry ice and stored at -80°C until required for analysis.  
 
Lipids were extracted from approximately 10 mg frozen brain tissue, using a modification of the 
single phase extraction method described by Bielawski et al [19]. A 1.5 mL mixture of ethyl 
acetate:isopropanol:water (30:10:60, v/v/v) (solution A), together with 1.5 mL chloroform/methanol 
(1:2) (solution B), was added to the frozen brain tissue in a 15 mL glass tube. A 50 µL cocktail of 
internal standards was added, comprising 5 µM each of d18:1/17:0 ceramide, d18:1/12:0 SM, and 
d18:1/12:0 GalCer. The brain tissue was further crushed with a dounce homogenizer, sonicated for 2 h 
in a Unisonics FXP10M water bath and incubated, with occasional sonicating, for 10 h at 35 °C to 
extract sphingolipids [12]. The extract was centrifuged for 10 min at 3700×g (25°C), and the 
supernatant transferred to a clean glass tube. The residue was re-extracted with 1.5 mL solution A as 
described above, then 1 mL chloroform/methanol (2:1). The supernatants from each extraction step 
were combined, divided into two parts, then dried down in a Thermo SC210 Speedvac. One half of 
the extract was reconstituted in 200 µL HPLC mobile phase (80:20 A/B), vortexed thoroughly, and 
centrifuged at 3700×g for 5 min (25°C). The supernatant was transferred to an HPLC vial with 200 
µL glass insert, and stored at –20°C until LC-MS/MS analysis of ceramide and GalCer/GluCer 
content. The other half of the extract was further processed for SM analysis, exactly as described 
previously [19]. Note that for SM preparation an alkaline hydrolysis step is included to remove 
phosphatidylcholine, which is highly abundant and may interfere with SM analysis. Analytical 
(HPLC) grade solvents were purchased from Merck. All lipid standards were purchased from Avanti 
Polar Lipids, except for SM(d18:1/22:0), which was from Matreya LLC.  
 
Data extraction and collation from multiple samples 
LC-MS/MS data from each sample was converted to mzXML file format using ReAdW (version 
4.3.1) [20] with default parameters. The data was then processed using in-house software: Mass 
spectra were de-isotoped based on the detection of estimated mass-dependent isotope profiles. In this 
process, the intensity of all isotopic peaks is combined into a single monoisotopic peak. Furthermore, 
water loss events (-18±0.25 m/z) were also removed from each spectrum. Peaks were then detected in 
each spectrum within the LC-MS/MS run. We defined a peak as ions with an intensity of greater than 
2.5% of the base peak and with at least 10,000 ion counts. To eliminate redundancy, all peaks with a 
similar mass (±0.25 m/z) and retention time (±0.5 minutes) arising from the same transition events 
across the chromatogram were culled, with the most intense peak within each mass and retention time 
window retained. To determine the abundance of a peak within a sample, the selected ion 
chromatogram is computed with a mass window of ± 0.25 m/z and smoothed using the Savitzky-
Golay filter [21] before the area under the chromatogram was calculated. This procedure results in a 
final list of peaks and their corresponding abundance for each selected reaction monitoring event. For 
MRM experiments, the precursor mass was used directly from each monitored event. 
 
For sample comparison, peak lists generated from each sample were further compiled to generate a 
list of peaks with aligned mass and retention times. The alignment process is based on the use of mass 
and retention time windows (± 0.5 m/z and ± 0.5 min, respectively). For the SM analysis, the retention 
time window was increased to ± 1.0 min to accommodate broader elution peaks, and to account for 
chromatographic variation between analyses which were performed over several days. We did not 
find it necessary to apply sophisticated non-linear alignment procedures [22]. 
 
This software tool is implemented using C++ and is available to the research community as a web 
resource, located at http://www.cancerresearch.unsw.edu.au/crcweb.nsf/page/lipidms. Source 
code will be made available to non-commercial users upon request. 
	  
Data Processing for 2D plots and Lipid Quantification 
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The RT vs m/z data for d18:1/(12:0, 14:0, 16:0, 18:0, 20:0, 22:0, and 24:0) ceramide standards was 
fitted to a centered second order polynomial equation, given by y = 9.423 + 0.0353(x – 566.5) + 
0.000133(x - 566.5)2 using GraphPad PRISM (R2 = 0.9994). For C18 chromatography, the 
relationship between m/z and RT was also quadratic, given by y = 9.610 + 0.09921(x – 576.7) + 
0.0005569(x – 576.7)2; R2 = 0.9987. This equation was then used to derive a theoretical RT for all m/z 
values. The theoretical RT was subtracted from the observed RT, yielding the relative RT (which is 
approximately 0 for all points used to fit the curve). There were insufficient commercially available 
GalCer and SM standards to derive the RT vs m/z relationship. We therefore extracted the m/z and RT 
for GalCer and SM bearing saturated N-acyl chains with an even number of carbons ranging from 16 
to 26 in length (i.e. d18:1/16:0 through to d18:1/26:0), in the collated hippocampus extracts. The RT 
values were compared to those observed with the commercially available standards (d18:1/16:0 and 
d18:1/18:0 for GalCer; d18:1/16:0, d18:1/22:0, and d18:1/24:0 for SM), to confirm that the RT values 
were accurate to within 0.1 min. The six data points obtained from the hippocampus extracts were 
then fitted to a centered second order polynomial (R2 = 0.9992 and 0.9993, for GalCer and SM, 
respectively) and relative RT values were obtained by fitting all observed m/z values to the equation 
and subtracting the resultant theoretical RT from the observed RT, as described above. Peak areas for 
each lipid identified were expressed as ratios to the relevant internal standard (d18:1/12:0 SM, 
d18:1/17:0 ceramide, or d18:1/12:0 GalCer), and normalized for the amount of starting brain tissue. 
For peaks identified by the m/z 264 product ion, the data was normalized separately to both ceramide 
and GalCer internal standards, yielding two distinct intensity plots.  
 
Ceramide and GalCer content (in pmoles/mg tissue) was calculated from standard curves constructed 
with available synthetic standards. In the case of GalCer, standards for d18:1/18:0 and d18:1/24:0 




Two-tailed t-tests were used to compare lipid levels or ratios between normal and AD hippocampus, 




Mass and Relative Elution Time (MRET) profiling approach 
In this article we use the LipidMAPS (www.lipidmaps.org) nomenclature system for sphingolipids, 
represented as “Lipid Class(length:double bonds of sphingoid base chain/length:double bonds of N-
acyl chain)”, e.g. SM(d18:1/24:0) refers to sphingomyelin with an 18-carbon sphingosine backbone 
with one double bond, and a 24-carbon N-acyl chain with no double bonds (Figure 1a). 
 
The aim of this project was to create a system that facilitates the use of column RT, as well as 
precursor and product masses, for characterising the sphingolipid content of complex biological 
extracts. To define a relationship between mass and RT, we first used a mixture of ceramide 
standards. We observed that the elution, from a C8 column, of ceramide standards ranging in N-acyl 
chain length from 12 to 24 carbons follows a quadratic relationship under isocratic elution conditions 
(100% methanol) (Figure 1b). Using this equation, we calculated the theoretical RT for each of a 
mixture of ceramide and dihydroceramide standards. The difference between observed and theoretical 
RT was termed “relative RT”, and plotted against m/z (Figure 1c). Ceramides differentiated only by 
the length of their N-acyl chain align horizontally, because they have an equivalent relative RT. 
Ceramides with an identical number of carbons but differing in the number of acyl chain double 
bonds align vertically. Ceramides with a 2-hydroxyl group in their N-acyl chain, referred to as 
Hydroxylated Fatty Acid (HFA) ceramides, are less hydrophobic and consequently have a more 
negative retention time relative to that expected for a Normal (i.e. non-hydroxylated) Fatty Acid 
(NFA) ceramide of equivalent mass. We next sought to determine if this approach would aid in the 
identification and characterization of sphingolipids in a complex biological extract. 
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Profiling the SM, Cer, and HexCer content of human brain tissue 
De novo sphingolipid synthesis gives rise to ceramides, which are then used to produce SM, GalCer, 
and GluCer (Figure 1a). GluCer and GalCer are geometric isomers, and therefore can not be resolved 
on the basis of mass or affinity for the C8 column. GalCer is one of the major brain lipids, estimated 
to comprise 20 – 25 % of the total lipid content of myelin [23]. It is approximately 200-fold more 
abundant in the human brain than GluCer [24, 25], and we therefore refer to the human brain 
hexosylceramides that we have detected as GalCer, noting that this analyte is predicted to contain 
approximately 0.5 mol % GluCer.  
 
We employed precursor ion scanning, using defined product ions with m/z 264 and 184, to identify 
the ceramide, GalCer, and SM species present in extracts of cerebellum and hippocampus from six 
AD patients, and six age- and gender-matched control subjects. The ion with m/z 264 is produced by 
sphingolipids with a d18:1 sphingosine backbone, whilst the ion with m/z 184 is the choline 
headgroup of SM. The LC-MS/MS data was processed as described in experimental procedures to 
generate a summary table showing m/z and RT values for all the distinct peaks in a set of samples, and 
the corresponding peak area (i.e. ion abundance) for that particular metabolite in each individual 
sample. 
 
The principle SM, ceramide, and GalCer components in the cerebellum and hippocampus extracts are 
shown in Figure 2, in which the mean peak area (n = 6) relative to other lipids is represented by the 
size of the bubble. A colour gradient is used to show abundance in AD, relative to control brain 
extracts. Lipids with no double bonds in their N-acyl chain, but differing in the number of N-acyl 
chain carbons align horizontally with a relative RT of approximately 0. Lipids with an identical 
number of carbons but differing degrees of unsaturation align vertically, as exemplified by the 
alignment of ions on the SM maps with m/z 811.7, 813.7, and 815.7, representing d18:1/24:2, 
d18:1/24:1, or d18:1/24:0 SM, respectively (Figure 2a). To confirm the identity of these products as 
SM species with a sphingosine backbone, we verified that both 184 (phosphatidylcholine) and 264 
(sphingosine backbone) m/z fragments were produced at the same column RT in a single sample run, 
after fragmentation of the m/z 731.6, 813.7, and 815.7 [SM(d18:1/18:0), SM(d18:1/24:1), and 
SM(d18:1/24:0)] precursor ions (collision energy 35 eV). Similarly, GalCer species with C24:1, 
C25:1, and C26:1 N-acyl chains (horizontal row at -1.0 to -1.1 min) align vertically with their C24:0, 
C25:0, and C26:0 counterparts (Figure 2c).  
 
We identified two horizontal series of lipids whose mass corresponds to GalCer with a hydroxylated 
fatty acid (i.e. HFA-GalCer; +16 Da), and 0 or 1 double bonds in their N-acyl chain, indicated by long 
arrows in Figure 2c. These lipids cluster in terms of m/z and RT with other GalCer species, but as 
would be expected for HFA-GalCer, they elute from the C8 column earlier than their NFA 
counterparts, with relative RT of -1.1 to -1.4 (22:0, 23:0, 24:0, 25:0, 26:0 N-acyl chains) and -1.9 to -
2.4 (23:1, 24:1, 25:1, 26:1 N-acyl chains), providing important evidence to confirm our prediction of 
their structure based on mass. Note that the shifted RT of these ions relative to their NFA counterparts 
also confirms that they are not oxidized GalCers, created during electrospray ionization. As expected, 
we observed no mass corresponding to the hydroxylated (m/z + 16) version of the GalCer(d18:1/12:0) 
internal standard. HFA lipids were observed only in GalCer, reflecting the strong preference of the 
enzyme UDP-galactose ceramide galactosyltransferase for HFA-ceramide substrates [26-28].  
 
The importance of using relative RT for lipid identification is emphasized by the presence of two 
distinct peaks for m/z 826.7 indicated by arrowheads in Figure 2c. Using the online metabolomic 
search tool METLIN, this metabolite is identified as GalCer(d18:1/25:0). In accordance with that 
prediction, one of the peaks with m/z 826.7 has a relative RT of -0.07 and sits on the y-axis. However, 
the second peak has a relative RT of -2.17, and based on its position on the 2D plot, we predict that 
this ion is HFA-GalCer(d18:1/24:1). It aligns horizontally with 840.7 and 854.7 Da ions, which 
correspond by mass to HFA-GalCer with 25:1 and 26:1 N-acyl chains. Because GalCer(d18:1/25:0) 
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and HFA-GalCer(d18:1/24:1) are separated in mass by only 0.04 Da and generate the same product 
ion (m/z 264), they would probably have been misconstrued as the same lipid, using any mass 
spectrometer other than a very high mass accuracy instrument. To further verify that these are indeed 
distinct GalCer species, we checked their mass and relative elution pattern on an LTQXL Orbitrap: 
m/z for the earlier eluting peak, predicted to be HFA-GalCer(d18:1/24:1), was 826.6741 (predicted 
mass 826.6767, machine accuracy -3.13 ppm); whilst for the later eluting peak, predicted to be NFA-
GalCer(d18:1/25:0), measured m/z was 826.7114 (predicted mass 826.7130, machine accuracy -1.99 
ppm).  
 
Another example further illustrates the importance of using relative RT in the identification of 
structure: in the ceramide plots an ion with m/z 664.6, indicated by an arrowhead in Figure 2e, could 
be either Cer(d18:1/25:0) or HFA-Cer(d18:1/24:1). Even in the absence of external standards for 
either of these lipids, we were readily able to identify this lipid as Cer(d18:1/25:0) based on its 
relative RT of 0.03 min. 
 
Decreased total GalCer and increased HFA:NFA GalCer ratio in Alzheimer’s Disease brains 
Visual inspection of Figure 2f suggested that NFA-GalCer content declined by more than 2-fold in the 
hippocampus of AD patients, whilst HFA-GalCer was less affected. The reduction in GalCer content 
per mg tissue in AD hippocampus was in itself not statistically significant, due to the large standard 
deviations that are to be expected with human subjects (P = 0.06). However, when normalised to the 
SM content in each sample (thereby offsetting the variation in total lipid content between samples), 
the decline in GalCer levels in AD hippocampus was statistically significant (Figure 3a). Note that 
total hippocampus SM content was unchanged (control: 1.12 ± 0.25 nmoles/mg tissue; AD: 1.18 ± 
0.24 nmoles/mg tissue (Mean ± Std Dev)). HFA-GalCer was significantly increased as a proportion of 
total GalCer (Figure 3b), and this altered HFA:NFA GalCer ratio was seen for all GalCer species 
(Figure 3c), suggesting either that fatty acid hydroxylase activity is increased or that catabolism of 
HFA-GalCer is slower than for NFA-GalCer in AD hippocampus. The only HFA-ceramide that could 
be detected was Cer(d18:1/24:0), which was present at detectable levels in all six of the AD 
hippocampus samples, but only one of the control samples. Having identified the major GalCer 
species present in human brain extracts using precursor ion scanning, we employed a more 
quantitative MRM approach to further test the utility of our relative elution time method and confirm 
the altered HFA:NFA-GalCer ratio in AD hippocampus.  
 
Application of the relative elution time method to Multiple Reaction Monitoring experiments 
Table 1 shows the MRM events we used and the specific species that we anticipated would be 
identified with each event. Figure 4a shows the total ion chromatogram for a single hippocampus 
sample, together with extracted ion chromatograms for the events with precursor ion m/z 826.7 or 
840.7. As described above, the two peaks observed for the m/z 826.7 ion are NFA-GalCer(d18:1/25:0) 
and HFA-GalCer(d18:1/24:1), which are separated in mass by only 0.04 Da. There are no synthetic or 
purified standards for these lipids, so they can only be differentiated either through further 
fragmentation studies, or on the basis of their RT relative to known standards, as illustrated in Figure 
4b. Similarly, two of the peaks observed in the m/z 840.7 event (Figure 4a) may be identified, based 
on their relative RT, as NFA-GalCer(d18:1/26:0) and HFA-GalCer(d18:1/25:1). The third, middle 
peak is a heavy isotope of NFA-GalCer(d18:1/26:1), which is removed by de-isotoping the data.  
 
As was observed with precursor ion scanning, there was a reduction in the NFA-GalCer content of 
AD hippocampus, compared to the controls (Figure 4b and Table 1). All NFA-GalCers were reduced 
in abundance, in AD compared to control hippocampus samples, and there were statistically 
significant reductions in a number of very long chain ceramides (Table 1). In contrast, HFA-GalCer 
content did not decrease. Rather, there was a slight increase in total HFA-GalCer content, and 
calculation of the HFA-GalCer content as a proportion of total GalCer confirmed the statistical 
significance of this difference between control and AD subjects (Figure 4c). 
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Applicability of the relative elution time method to C18 chromatography 
To demonstrate the portability of our method to other column types, we ran our mixture of ceramide 
and dihydroceramde standards and one of the hippocampus extracts on a C18 column, which are 
commonly used in sphingolipid analyses. As expected, the quadratic relationship between column RT 
and mass was also seen with this column (eluting under isocratic conditions with 100% methanol) 
(Figure 5a). The same relationship between RT and mass is observed when the ceramides are eluted 
with 90% isopropanol/10% water (data not shown). The pattern of hippocampal galactosylceramides 
eluting from the C18 column was very similar to that observed with a C8 column. Column RT for 
GalCer species with a sphingosine base and a saturated N-acyl chain (i.e. d18:1/N:0) followed a 
quadratic relationship with respect to mass, and after application of our RT transform the NFA-




The lipid profiling approach that we describe represents a significant improvement over current 
methods because the physicochemical characteristics of the lipids facilitate their identification. These 
characteristics may be critically important in resolving structurally different lipids that have almost 
identical mass and are within the same broad functional class, as in the example we present with 
NFA-GalCer(d18:1/25:0) and HFA-GalCer(d18:1/C24:1). Approaches that employ the 
physicochemical characteristics of lipids, including multi-dimensional mass spectrometry (MDMS)-
based shotgun lipidomics [29] and TLC-MALDI [30], have been employed to separate different 
classes of lipids before MS analysis, but not to separate lipids within the same structural class. In fact, 
shotgun approaches such as MDMS are unable to resolve HFA- and NFA-GalCers that have almost 
identical mass [31]. The relative RT method that we describe herein greatly aids in the identification 
of lipids within the same structural class and in determining whether a particular metabolite belongs to 
a particular lipid class. We note that current published protocols for comprehensive sphingolipidomic 
analysis do not incorporate monitoring of HFA-GalCer [11, 12]. Although we employed a high mass 
accuracy Orbitrap instrument to verify our method, the use of these instruments is inherently more 
complex and they can not be set to perform precursor ion scans with defined product ions or multiple 
reaction monitoring. 
 
In addition to improving the accuracy of lipid structure characterization, the resultant 2D plots greatly 
improve visualization of the data, when compared to a tabulated list. A recent review identified 
visualization of data as one of the key issues in sphingolipidomic systems analysis [1]. To illustrate 
this point, a 2D map of the MS intensity output using precursor ion scanning over the m/z range 680 – 
900 (product ion m/z 264), from a single cerebellum sample before and after RT transformation is 
shown in Supplementary Figure 1. Plotting distinct LC peaks (as in Figure 2) rather than the raw 
intensity data (Supplementary Figure 1) improves the visual appearance of the data and makes it much 
simpler to present the mean of multiple samples, thereby improving our capacity to draw meaningful 
inferences from the data. Using our method, we could readily visualize the GalCer content of brain 
samples taken from AD patients and normal controls. Synthetic or purified standards are not available 
for most of the GalCer species shown in Figures 2 and 4, which makes the unambiguous assignment 
of lipid structure based on the most commonly employed MS1 or MS2 approaches impossible. More 
detailed analyses of the fragmentation pattern of individual lipids generally reveals the structure, but 
this is not always the case and this approach often necessitates chemical derivatization of lipids prior 
to MS analysis or the use of more reactive collision gases [32]. Using our approach, chemical 
derivatization is not necessary and important biochemical information can be obtained for many lipids 
simultaneously. 
 
It is well established in the literature that precursor ion scanning, because of its reduced duty cycle, is 
less quantitative than MRM approaches. However, we believe that precursor ion scans such as we 
have used in this study are an important tool for establishing the principal lipids of interest for 
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subsequent MRM experiments, and are a valid approach for establishing trends in the data. We found 
that the principal trends observed using precursor ion scanning - a reduction in total GalCer content 
and an increase in HFA-GalCer content as a proportion of the total GalCer content - were reproduced 
in MRM mode which, as expected, yielded a greater linear range for absolute quantification. Although 
ceramide 1-phosphates were not abundant in the brain tissues analyzed in this study, we have found 
that the precursor ion scan with product ion m/z 264 used in this study is also sufficient to detect gross 
changes in ceramide 1-phosphate content in cultured cells. We have been unable to detect the 
principle dihydroceramide species using precursor ion scanning coupled to a product ion m/z of 266, 
due to their low abundance and their relatively poor fragmentation to the m/z 266 backbone ion 
(compared to the m/z 264 ion characteristic of sphingosine). However, we have found that 
sphingolipids bearing a sphinga-2,4-diene backbone can readily be identified with a precursor scan 
coupled to a product ion with m/z 262 (Supplementary Figure 1c) [33].  
 
This is the first study to demonstrate an increase in the ratio of HFA-GalCer:NFA-GalCer in the 
brains of AD patients. This change was accompanied by an overall decline in hippocampal GalCer 
content, although not statistically significant in this study. The loss of GalCer in AD is in agreement 
with older literature employing thin layer chromatography techniques [34, 35]. These changes were 
observed in the hippocampus but not the cerebellum, in accordance with the pathology of AD: 
hippocampal atrophy associated with a pronounced loss of pyramidal neurons is a defining feature of 
AD, whilst the cerebellum is much less affected [36, 37]. More recent mass spectrometry analysis has 
shown a decline in sulfatide content, in the absence of any decline in GalCer content, in various 
regions of the cerebral cortex of AD subjects [38]. We note that these authors did not examine 
changes in the hippocampus, whilst we did not examine any frontal or temporal cortex tissue. In 
future studies, we aim to investigate the changes to these myelin sphingolipids using a much larger 
cohort of patient samples.  
 
We found HFA-GalCer to comprise approximately 50% of total GalCer in the cerebellum, and 20% in 
the hippocampus of control subjects. Previous studies have reported that HFA-GalCer comprises 
approximately half of total GalCer in myelin [39, 40]. Whilst very long chain ceramides (those with 
>24 carbon N-acyl chains) declined in abundance in AD hippocampus, we observed an increase in the 
only detectible HFA-ceramide, d18:1/24:0 (Table 1). In precursor scanning mode, HFA-
Cer(d18:1/24:0) was detected in all six AD hippocampus samples, but only one of the control 
hippocampus samples. These results suggest increased fatty acid hydroxylase activity in AD. Barrier 
et al [41] have very recently reported an increase in the ratio of HFA-ceramide:NFA-ceramide in the 
cerebral cortex, in a mouse model of AD (APPSL/PS1 Ki). Interestingly, the increased ratio was only 
observed in female mice. Our human cohort is too small to draw firm conclusions on sex-related 
differences (see Table 2), but we note that when separated on the basis of gender, the HFA:NFA 
GalCer ratio was significantly different between AD and control females (P = 0.0006), but not males.  
 
In summary, a rapidly growing body of literature is now highlighting the importance of lipid 
metabolites to cell signaling and pathophysiological processes. We present a new method that 
improves the combined use of liquid chromatography and mass spectrometry to create a 2D analysis 
of sphingolipids in a complex biological extract. The data transform that we apply can in theory be 
applied to any chromatography in which the separation of different lipids within the same functional 
class is dependent on the length of the lipid tails. The increased capacity of our approach to 
objectively profile lipid content is illustrated with the new findings we describe regarding changes in 
the sphingolipid content in the brains of AD patients. Our approach can be applied to other classes of 
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TABLES 
Table 1. Abundance of individual ceramide and GalCer species in human hippocampus 
extracts, as determined by MRM. 
Lipids possess non-hydroxylated fatty acid (NFA) chains, unless HFA is prefixed to the name. 
Different lipids sharing the same precursor mass were differentiated on the basis of relative RT. The 
product m/z was set at 264.1 for all events, whilst collision energy was set at 30 eV for ceramides and 
35 eV for GalCers. Note that internal standards Cer(d18:1/17:0) and GalCer(d18:1/12:0) were 
detected with precursor m/z 552.7 and 644.6, respectively. Units of abundance are pmoles lipid/mg 
tissue, and values shown are the mean ± standard deviation of six patient samples. Dash indicates that 
lipid was not quantified due to very low abundance. Asterisk (*) indicates a statistically significant 
difference (P < 0.05) between control and AD hippocampus, as determined by two-tailed t-test. 
 




Cer(d18:1/16:0) 538.6 0.30 ± 0.15 0.52 ± 0.23 
Cer(d18:1/18:1) 564.6 - - 
Cer(d18:1/18:0) 566.7 6.44 ± 2.46 6.43 ± 4.31 
Cer(d18:1/20:0) 594.7 0.12 ± 0.033 0.18 ± 0.10 
Cer(d18:1/22:0) 622.7 0.10 ± 0.040 0.098 ± 0.022 
Cer(d18:1/23:1) 634.7 - - 
Cer(d18:1/23:0) 636.7 0.097 ± 0.042 0.060 ± 0.022 
Cer(d18:1/24:1) 648.8 2.81 ± 1.11 1.52 ± 0.83* 
Cer(d18:1/24:0) 650.8 0.27 ± 0.14 0.15 ± 0.068 
Cer(d18:1/25:1) 662.8 0.55 ± 0.27 0.23 ± 0.15* 
Cer(d18:1/25:0) 664.8 0.043 ± 0.026 0.015 ± 0.0098* 
HFA-Cer(d18:1/24:0) 666.8 0.0089 ± 0.0084 0.0139 ± 0.0062 
Cer(d18:1/26:1) 676.8 0.25 ± 0.096 0.081 ± 0.051* 
Cer(d18:1/26:0) 678.8 - - 
    
Total Ceramide  10.96 ± 3.14 9.28 ± 4.92 
    
GalCer(d18:1/16:0) 700.7 3.00 ± 1.82 2.08 ± 1.31 
GalCer(d18:1/18:1) 726.7 - - 
GalCer(d18:1/18:0) 728.7 184.5 ± 89.5 106.2 ± 120.9 
HFA-GalCer(d18:1/18:1) 742.7 - - 
HFA-GalCer(d18:1/18:0) 744.7 7.38 ± 3.25 5.98 ± 3.68 
GalCer(d18:1/20:1) 754.7 - - 
GalCer(d18:1/20:0) 756.7 10.97 ± 3.73 7.16 ± 8.59 
HFA-GalCer(d18:1/20:1) 770.7 - - 
HFA-GalCer(d18:1/20:0) 772.7 - - 
GalCer(d18:1/22:1) 782.7 6.87 ± 2.73 4.06 ± 4.65 
GalCer(d18:1/22:0) 784.7 39.95 ± 13.83 26.82 ± 24.85 
GalCer(d18:1/23:1) 796.7 22.91 ± 10.24 11.51 ± 12.36 
GalCer(d18:1/23:0) 798.7 64.11 ± 20.91 40.89 ± 27.20 
HFA-GalCer(d18:1/22:1) 798.7 - - 
HFA-GalCer(d18:1/22:0) 800.7 23.48 ± 9.99 28.21 ± 9.06 
GalCer(d18:1/24:1) 810.7 685.3 ± 291.1 387.9 ± 366.6  
GalCer(d18:1/24:0) 812.7 247.5 ± 85.6 155.8 ± 106.8 
HFA-GalCer(d18:1/23:1) 812.7 - - 
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HFA-GalCer(d18:1/23:0) 814.7 34.06 ± 18.47 47.20 ± 18.74 
GalCer(d18:1/25:1) 824.8 202.4 ± 84.7 122.1 ± 89.7 
GalCer(d18:1/25:0) 826.8 85.77 ± 28.99 56.96 ± 43.49 
HFA-GalCer(d18:1/24:1) 826.8 168.1 ± 70.0 142.6 ± 50.1 
HFA-GalCer(d18:1/24:0) 828.8 53.80 ± 28.07 67.57 ± 33.13 
GalCer(d18:1/26:1) 838.8 208.5 ± 57.9 126.5 ± 66.1* 
GalCer(d18:1/26:0) 840.8 30.21 ± 7.70 20.02 ± 17.30 
HFA-GalCer(d18:1/25:1) 840.8 19.81 ± 12.67 32.22 ± 16.82 
HFA-GalCer(d18:1/25:0) 842.8 14.70 ± 8.28 21.17 ± 8.54 
HFA-GalCer(d18:1/26:1) 854.8 21.55 ± 10.65 40.33 ± 23.28 
HFA-GalCer(d18:1/26:0) 856.8 9.57 ± 3.38 8.50 ± 3.79 
    
Total Galcer  2145 ± 741 1462 ± 888 
Total NFA-GalCer  1792 ± 613 1068 ± 860 
Total HFA-GalCer  352.5 ± 148.6 393.7 ± 135.5 
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Table 2. Patient brain samples used in this study 
PMI, post-mortem interval; NFT, neurofibrillary tangle 
ID# age gender 
PMI 






1 85 female 23 pneumonia 0 0 
2 79 male 8 pulmonary embolism 0 0 
3 93 female 21 cardiac failure 0 0 
4 78 female 11 respiratory failure 0 0 
5 69 male 13.5 myocardial infarction 0 0 
6 82 male 23.5 multiple organ failure 0 0 
7 83 male 25 cerebrovascular accident 5 stage VI 
8 84 female 6 aspiration pneumonia 13 stage VI 
9 83 female 3 uraemia 7 stage V 
10 73 male 16 bronchopneumonia 11 stage VI 
11 83 female 4 circulatory collapse 9 stage V 
12 69 male 3 colon cancer 5 stage VI 
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FIGURE LEGENDS	  
Figure 1. Two dimensional separation of ceramide standards according to mass and 
hydrophobicity. (a) Structure and biochemical relationship of SM, ceramide, and GalCer. (b) Plot of 
RT against m/z for a mixture of 16 different ceramide (Cer) and dihydroceramide (dhCer) standards, 
as analysed by LC-MS/MS (10 pmole each). Lipids were separated on a C8 column and individual 
species were identified by precursor ion scanning, monitoring for 264 and 266 Da product ions, at 30 
eV. The curve is a centered second order polynomial, fitted to the following 7 standards: d18:1/12:0 
(C12:0 Cer), d18:1/14:0 (C14:0 Cer), d18:1/16:0 (C16:0 Cer), d18:1/18:0 (C18:0 Cer), d18:1/20:0 
(C20:0 Cer), d18:1/22:0 (C22:0 Cer), and d18:1/24:0 (C24:0 Cer). The other standards shown are: 
d18:0/16:0 (C16:0 dhCer), d18:0/18:0 (C18:0 dhCer), d18:0/24:0 (C24:0 dhCer), d18:0/18:1 (C18:1 
dhCer); d18:0/C24:1 (C24:1 dhCer); d18:1/18:1 (C18:1 Cer); d18:1/24:1 (C24:1 Cer); d18:1/18:0(2-
OH) (C18:0 HFA-Cer) and d18:1/24:0(2-OH) (C24:0 HFA-Cer). (c) Relative RT plotted against m/z 
for all 16 standards. The identity of each standard is indicated on the graph. Note the vertical 
alignment of standards with equivalent or almost equivalent mass, but a different number or position 
of double bonds, indicative of separation based on hydrophobicity.  
 
Figure 2. 2D plots of sphingolipid content in cerebellum and hippocampus: comparison of 
control to AD brains. SM (a and d), ceramide (b and e), and GalCer (c and f) content of cerebellum 
(a-c) and hippocampus (d-f). Each bubble represents a distinct ion peak on a plot of relative RT vs 
m/z, and the size of the bubble is indicative of peak area after adjusting for internal standard recovery 
and mass of homogenized tissue. Bubble sizes shown (i.e. adjusted peak areas) are the mean of six 
samples, and for clarity in presentation, the sizing of the bubbles is normalized within each functional 
class, i.e. SM, Cer and GalCer. The colour gradient indicates intensity of that metabolite in AD 
samples (mean of 6), relative to control (mean of 6). Red: increased in AD; Blue: decreased in AD 
brains. Relative RT was derived by transformation of RT for each corresponding m/z, relative to SM, 
ceramide or GalCer with saturated N-acyl chains, as described in experimental procedures. C16, C18, 
C20, C22, C24, and C26 refer to the length of N-acyl chains, as determined by mass and referenced to 
external standards. Horizontal arrows show rows of HFA-GalCer species. Arrowheads in (c) indicate 
the position of two distinct bubbles with an m/z of 826.7, which are GalCer(d18:1/25:0), at Relative 
RT = 0; and HFA-GalCer(d18:1/24:1), at Relative RT = -2.2. Arrowhead in (e) indicates position of 
Cer(d18:1/25:0). 
 
Figure 3. Decreased GalCer and increased GalCer hydroxylation in AD hippocampus. (a) Total 
GalCer content is expressed relative to total SM content in each of the brain samples. Horizontal bars 
show the mean (n = 6). (b) Scatter plots showing total HFA-GalCer peak area, as a proportion of total 
(HFA-GalCer + NFA-GalCer) peak area. (c) HFA-GalCer peak area, as a proportion of total (HFA-
GalCer + NFA-GalCer) peak area, for each different N-acyl chain length. Values are mean ± standard 
error (n = 6). P values were derived from unpaired, two-tailed t-tests.  
 
Figure 4. Use of relative elution time to confirm identity of GalCer species in MRM. (a) Total Ion 
Chromatogram (TIC) and extracted chromatograms for the m/z 826.7 and 840.7 events, for a 
hippocampus extract from a control patient analysed in MRM mode (events shown in Table 1). (b) 
Relative RT vs m/z plot showing GalCer peaks detected in MRM mode. Bubbles illustrate the relative 
abundance of each metabolite in all six control hippocampus extracts, and colour gradient describes 
the abundance of each metabolite in the six AD, relative to the control, hippocampus extracts. (c) 
HFA-GalCer as a proportion of total GalCer (HFA + NFA), for each of the control (n = 6) and AD (n 
= 6) hippocampus samples. P value was derived from a two-tailed t-test.  
 
Figure 5. Application of relative elution time method with a C18 chromatography column. (a) 
Elution pattern for a mixture of ceramide standards eluted from a C18 column under isocratic 
conditions (100% methanol); (i) shows absolute RT; whilst (ii) shows relative RT. Using a C18 
column, the relationship between m/z and RT fits a quadratic equation. (b) Relative RT vs m/z plot of 
the GalCer content in a control hippocampus extract, using a C18 chromatography column.
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Figure 5 
 
